pharmaceutical: search

PHARMACEUTICAL COMPOSITION COMPRISING HIGH-POTENCY SWEETENER [European Patents]

PRAKASH, Indra DUBOIS, Grant, E. Title PHARMACEUTICAL COMPOSITION COMPRISING HIGH-POTENCY SWEETENER Abstract The present invention relates generally to pharmaceutical compositions comprising non-caloric or low-caloric high-potency sweeteners and methods for making and using them, in particular, the present invention relates to different pharmaceutical compositions comprising at least one non-caloric or low-caloric natural and/or synthetic high-potency sweetener, at least one sweet taste improving composition, and a pharmaceutically active substance. The present invention also relates to pharmaceutical compositions and methods that can improve the tastes of non-caloric or low-caloric natural and/or synthetic, high- potency sweeteners by imparting a more sugar-like taste or characteristic.

Generex Biotechnology Awarded New Drug Delivery Patent

Generex Biotechnology Corporation announced that it has received a new patent in Australia. The Australian Patent Office has granted the Company a patent titled Micellar Pharmaceutical Compositions for Buccal and Pulmonary Application. The patent contains formulation and method claims to a pharmaceutical formulation comprising a macromolecular pharmaceutical agent in mixed micellar form, and metered dose device containing said formulation, for buccal administration.

EU Pharmaceutical Companies Abuse Patents To Block... (DJ)

BRUSSELS -(Dow Jones)- Big pharmaceutical companies abuse their position in the marketplace to delay and block new, often cheaper, drugs from coming to market, the European Commission said Friday.

EU: Pharmaceutical Companies Abuse Patents To Block Competition

(Dow Jones)- Big pharmaceutical companies abuse their position in the marketplace to delay and block new, often cheaper, drugs from coming to market, the European Commission said Friday.

Are pharmaceutical patents protected by human rights?

Millum J et al. - The International Bill of Rights enshrines a right to health, which includes a right to access essential medicines. This right frequently appears to conflict with the intellectual property regime that governs pharmaceutical patents. This article examines the recent attempt by the Committee on Economic, Social and Cultural Rights to resolve this issue and argues that it fails. This is problematic because it means defenders of the present patent regime can continue using human rights documents to support their position.

Northeastern's Center for Pharmaceutical Biotechnology and Nanomedicine Receives $1.5M NIH Grant to Examine Drug Delivery

Home > Press > Northeastern’s Center for Pharmaceutical Biotechnology and Nanomedicine Receives $1.5M NIH Grant to Examine Drug Delivery

Robotic Loading/Unloading System for High Speed Medical Device and Pharmaceutical Packaging Lines

AddThis press release: Robotic Loading/Unloading System for High Speed Medical Device and Pharmaceutical Packaging Lines

Micromeritics Presents The College Of Pharmacy, University Of Tennessee Health Science Center, With A Distinguished Pharmaceutical Education Support Donation

Micromeritics Presents The College Of Pharmacy, University Of Tennessee Health Science Center, With A Distinguished Pharmaceutical Education Support Donation

Research and Markets: A Detailed Company Profile of Chattem, Inc: Providing Data on Patents, Company Financials and the U.S. Pharmaceutical Preparation Manufacturing Industry

DUBLIN, Ireland--(BUSINESS WIRE)--Dec 2, 2008 - Research and Markets (http://www.researchandmarkets.com/research/18f6ed/chattem_inc_and) has announced the addition of the "Chattem, Inc. and the U.S. Pharmaceutical Preparation Manufacturing Industry" company profile to their offering.

Indian pharma cos fail to compete with foreign players in securing product patents for innovations

Indian pharmaceutical companies and individuals together could grab just above 15 per cent of the total product patents granted to pharmaceutical inventions and innovations in the past three years from January 1, 2005, ever since the country moved into the product patent regime from process patents.

General Patent is Successful in Litigation to Enforce "Smart Connector" Patents

This 2008 China Pharmaceutical Regulatory Report Includes a Brief Overview of the Pharmaceutical and Healthcare industry in China

ScinoPharm gets US patent for novel crystal forms of Irinotecan Hydrochloride

ScinoPharm, an active pharmaceutical ingredient (API) specialist, has been granted US Patent No. 7,435,818 entitled "Novel Crystal Forms of Irinotecan Hydrochloride." The new patent provides for novel crystalline forms of irinotecan hydrochloride and processes for their preparation as well as pharmaceutical compositions containing the new forms and methods of treating metastatic carcinoma of the colon or rectum using these new forms.

Dong-A wins US patent lawsuit

Singapore, Nov 5, 2008: Dong-A Pharmaceutical, a Korean pharmaceutical company, has won the case in an international arbitration brought by an US biotech venture.

ScinoPharm wins new US patent for crystal forms of oncology product

ScinoPharm, a supplier of active pharmaceutical ingredients, has received a new US patent, which provides for novel crystalline forms of irinotecan hydrochloride and processes for their preparation as well as pharmaceutical compositions containing the new forms and methods of treating metastatic carcinoma of the colon or rectum using these new forms.

ScinoPharm Granted US Patent for Novel Crystal Forms

PRNewswire-Asia/ -- ScinoPharm, an active pharmaceutical ingredient (API) specialist, announced it has been granted US Patent No. 7,435,818 entitled "Novel Crystal Forms of Irinotecan Hydrochloride." The new patent provides for novel crystalline forms of irinotecan hydrochloride and processes for their preparation as well as pharmaceutical compositions containing the new forms and methods of treating metastatic carcinoma of the colon or rectum using these new forms.

AOB Has the Herbal Remedy - Analyst Blog

(AOB) is a China-based specialty pharmaceutical company which develops, manufactures and commercializes both plant-based pharmaceutical (PBP) and plant-based nutraceutical (PBN) products. Third quarter financials were strong and in line with our expectations.

Zydus Says Teva Patents Violate Antitrust Laws

Law360, New York (October 28, 2008) -- India-based pharmaceutical company Zydus Cadila’s U.S. subsidiary has filed a lawsuit against Teva Pharmaceutical Industries Ltd., accusing the Israeli generic-drug maker of deceptive trade practices related to the schizophrenia treatment risperidone.

ScinoPharm Granted US Patent for Novel Crystal Forms

TAINAN, Taiwan, Nov. 25 /PRNewswire-Asia/ -- ScinoPharm, an active pharmaceutical ingredient (API) specialist, announced it has been granted US Patent No. 7,435,818 entitled "Novel Crystal Forms of Irinotecan Hydrochloride." The new patent provides for novel crystalline forms of irinotecan hydrochloride and processes for their preparation as well as pharmaceutical compositions containing the new forms and methods of treating metastatic carcinoma of the colon or rectum using these new forms.

ScinoPharm Granted US Patent for Novel Crystal Forms

TAINAN, Taiwan, Nov. 25 /PRNewswire-Asia/ -- ScinoPharm, an active pharmaceutical ingredient (API) specialist, announced it has been granted US Patent No. 7,435,818 entitled "Novel Crystal Forms of Irinotecan Hydrochloride." The new patent provides for novel crystalline forms of irinotecan hydrochloride and processes for their preparation as well as pharmaceutical compositions containing the new forms and methods of treating metastatic carcinoma of the colon or rectum using these new forms.

ScinoPharm Granted US Patent for Novel Crystal Forms

TAINAN, Taiwan, November 25, 2008 /PRNewswire-Asia/ -- ScinoPharm, an active pharmaceutical ingredient (API) specialist, announced it has been granted US Patent No. 7,435,818 entitled "Novel Crystal Forms of Irinotecan Hydrochloride." The new patent provides for novel crystalline forms of irinotecan hydrochloride and processes for their preparation as well as pharmaceutical compositions containing the new forms and methods of treating metastatic carcinoma of the colon or rectum using these new forms.

Evotec-RSIL Ltd announces two key library synthesis collaborations and celebrates its first full year of operations

Evotec-RSIL Ltd is pleased to announce two new contracts with global pharmaceutical companies for the synthesis and supply of compound libraries. These follow a successful year of operations which has seen them sign collaborations with a total of five companies. In the latest deals Evotec-RSIL Ltd has signed contracts with major pharmaceutical companies from Europe and the United States. In both deals Evotec-RSIL Ltd will use its skills and expertise in parallel synthesis, purification and analysis to synthesise and purify hit discovery libraries of hundreds to thousands of high quality compounds in the format specified by the customer.

2nd UPDATE Sanofi Settles Some US Allegra Patent Suits (DJ)

By Geraldine Amiel Of DOW JONES NEWSWIRES PARIS -(Dow Jones)- Sanofi-Aventis (SNY) Wednesday said it agreed to settle some patent infringement suits in the U.S. with drug makers Barr Pharmaceuticals Inc (BRL) and Teva Pharmaceutical Industries Ltd (TEVA) over their generic versions of the French pharmaceutical giant's anti-allergy drug Allegra.

UPDATE Sanofi Settles Some Allegra, Nasacort Patent Suits (DJ)

By Geraldine Amiel Of DOW JONES NEWSWIRES PARIS -(Dow Jones)- Sanofi-Aventis (SNY) Wednesday said it agreed to settle some patent infrigement suits in the U.S. with drug makers Barr Pharmaceuticals Inc (BRL) and Teva Pharmaceutical Industries Ltd (TEVA) over their generic versions of the French pharmaceutical giant's anti-allergy drug Allegra.

Search took 0.03 seconds.